Compare WB & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WB | IMNM |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2014 | 2020 |
| Metric | WB | IMNM |
|---|---|---|
| Price | $7.78 | $22.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $14.00 | ★ $32.80 |
| AVG Volume (30 Days) | 947.0K | ★ 1.6M |
| Earning Date | 05-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.49% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | $8.35 | N/A |
| Revenue Next Year | $1.73 | $1,127.34 |
| P/E Ratio | $5.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.09 | $8.67 |
| 52 Week High | $12.96 | $27.65 |
| Indicator | WB | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 55.60 | 51.85 |
| Support Level | $7.09 | $19.28 |
| Resistance Level | $10.49 | $23.25 |
| Average True Range (ATR) | 0.14 | 1.16 |
| MACD | 0.05 | -0.11 |
| Stochastic Oscillator | 64.23 | 17.74 |
Weibo Corp is a China-based company mainly engaged in the social media advertising business for people to create, discover and distribute content. The company's activities include Advertising and Marketing, which mainly provides a full range of advertising customization and marketing solutions. The Value-added Services mainly provide services such as membership services on social platforms, online games, live broadcasts, social e-commerce, and others. The Company's main product is the social platform Weibo.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.